Implications of the cancer stem cell hypothesis for neuro-oncology and neurology

Future Neurology

Volumn 3, Issue 3, 2008, Pages 265-273

  Rich, Jeremy N ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain tumor; Cancer stem cell; CD133; Cell of origin; Glioblastoma; Glioma; Medulloblastoma; Neurosphere; Prominin 1; Stem cell

Indexed keywords

ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BMI1 PROTEIN; BONE MORPHOGENETIC PROTEIN; CA 125 ANTIGEN; CANCER VACCINE; CD133 ANTIGEN; EPIDERMAL GROWTH FACTOR; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; LEUCINE ZIPPER PROTEIN; NOTCH RECEPTOR; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; SONIC HEDGEHOG PROTEIN; TEMOZOLOMIDE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRAIN CANCER; BRAIN RADIATION; CANCER IMMUNIZATION; CANCER INVASION; CANCER MORTALITY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL FATE; CELL RENEWAL; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG TARGETING; EARLY DIAGNOSIS; GLIOBLASTOMA; GLIOMA; HUMAN; HYPOTHESIS; METASTASIS POTENTIAL; MOLECULAR IMAGING; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; REVIEW; STEM CELL TRANSPLANTATION; TUMOR VASCULARIZATION; VIROTHERAPY;

EID: 44149118892     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.3.265     Document Type: Review

References (73)

1. Furnari FB, Fenton T, Bachoo RM et al.: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21(21), 2683-2710 (2007).
2. Kelly PN, Dakic A. Adams JM, Nutt SL, Strasser A: Tumor growth need not be driven by rare cancer stem cells. Science 317, 337 (2007).
3. Vescovi AL, Galli R, Reynolds BA: Brain tumour stem cells. Nat. Rev. Cancer 6(6), 425-436 (2006).
4. Ward RJ, Dirks PB: Cancer stem cells: at the headwaters of tumor development. Annu. Rev. Pathol. 2, 175-189 (2007).
5. Rich JN: Cancer stem cells in radiation resistance. Cancer Res. 67(19), 8980-8984 (2007).
6. Sanai N, Alvarez-Buylla A, Berger MS; Neural stem cells and the origin of gliomas. N. Engl. J. Med. 353(8), 811-822 (2005).
7. Taylor MD, Poppleton H, Fuiler C et al.: Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8(4), 323-335 (2005).
8. Zhu Y, Guignard F, Zhao D et al.: Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8(2), 119-130 (2005).
9. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25(1), 55-57 (2000).
10. Ligon KL, Huillard E, Mehta S et al.: Olig2-regulated lineage-restricted pathway controls replitation competence in neural stem cells and malignant glioma. Neuron 53(4), 503-517 (2007).
11. Bachoo RM, Maher EA, Ligon KL et al.: Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1, 269-277 (2002).
12. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC: Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res. 62(19), 5551-5558 (2002).
13. Ubrbom L, Kastemar M, Johansson FK, Westermark B, Holland EC: Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis. Cancer Res. 65(6), 2065-2069 (2005).
14. Bruggeman SW, Hulsman D, Tanger E et al.: BMI1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell 12(4), 328-341 (2007).
15. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
16. Dalerba P, Cho RW, Clarke MF: Cancer stem cells: models and concepts. Annu. Rev. Med. 58, 267-284. (2007).
17. Uchida N, Buck DW, He D et al.: Direct isolation of human central nervous system stem cells. Proc. Natl Acad Sci. USA 97(26), 14720-14725 (2000).
18. Singh SK, Hawkins C, Clarke ID et al.: Identification of Human brain rumour initiating cells. Nature 432, 396-401 (2004).
19. Singh SK, Clarke ID, Terasaki M et al.: Identification of a cancer stem cell in human brain Tumors. Cancer Res. 63(18), 5821-5828 (2003).
20. Galh R, Binda E, Orfanelli U et al.: Isolation and characterization of rumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64(19), 7011-7021 (2004).
21. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. Human cortical glial rumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39(3), 193-206 (2002).
22. Hemmati HD, Nakano i, Lazareff JA et al.: Cancerous stem cells can arise from pediatric brain rumors. Proc. Natl Acad. Sci. USA 100(25), 15178-15183 (2003).
23. Lee J, Kotliarova S, Kotliarov Y et al.: Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9(5), 391-403 (2006).
24. Yuan X, Curtin J, Xiong Y et al.: Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23(58), 9392-9400 (2004).
25. Singec I, Knoth R, Meyer RP et al.: Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology. Nat. Methods 3(10), 801-806 (2006).
26. Lapidot T, Shard C, Vormoor J et al.: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-(A8 (1994).
27. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 3, 730-737 (1997).
28. Al-Hajj M, Wicha MS, Benito-Hernandez; A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad Sci. USA 100, 3983-3988. (2003).
29. Pfenninger CV, Roschupkina T, Hertwig F et al.: CD 133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells, Cancer Res. 67(12), 5727-5736 (2007).
30. Bao S, Wu Q, McLendon RE et al.: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760 (2006).
31. Beier D, Hau P, Proescholdt M et al.: CD133' and CD133 glioblastoma-derived cancer stem cells show differential growth, characteristics and molecular profiles. Cancer Res. 67, 4010-4015 (2007).
32. Zheng X, Shen G, Yang X, Liu W. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res. 67(8), 3691-3697 (2007).
33. Wang J, Sakariassen PØ, Tsinkalovsky O et al.: CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 122(4), 761-768 (2008).
34. Balend L, Saoudi Y, Grunwald D et al.: IQGAPI regulates adult neural progenitors in vivo and vascular endothelial growth factor-triggered neural progenitor migration in vitro. J Neurosci. 27(17), 4716-4724 (2007).
35. Balenci L, Clarke ID, Dirks PB et al.: IQGAPI protein specifies amplifying cancer cells in glioblastoma multiforme. Cancer Res. 66(18), 9074-90782 (2006).
36. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100, 57-76 (2000).
37. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A: HEDGEHOG-GLII signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17(2), 165-172 (2007).
38. Bar EE, Chaudhry A, Lin A et al.: Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25(10), 2524-2533 (2007).
39. Fan X, Matsui W, Khaki L et al.: Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 66, 7445-7452 (2006).
40. Molofsky AV, Pardal R, Iwashita T et al.: Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425, 962-967 (2003).
41. Piccirillo SG, Reynolds BA, Zanetti N et al.: Bone morphogenetic proteins inhibit the tumaorigenic potential of human brain tumour initiating cells. Nature 444(7120), 761-765 (2006).
42. Ehtesham M, Sarangi A, Valadez JG et al.: Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene 26(39), 5752-5761 (2907).
43. Lee J, Son MJ, Woolard K et al.: Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 13(1), 69-810 (2008).
44. Nakano I, Masterman-Smith M, Saigusa K et al.: Maternal embryonic leucine zipper kinase is a key regulator of die proliferation of malignant brain tumors, including brain tumor stem cells. J. Neurosci. Res. 86(1), 48-60 (2007).
45. Stupp R, Mason WP, van den Bent MJ et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
46. + sector is enlarged by hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 67(1), 1-5 (2007).
47. Liu G, Yuan X, Zeng Z et al.: Analysis of gene expression and chemoresistance of CD133′ cancer stem cells in glioblastoma. Mol. Cancer 5, 67 (2006).
48. Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS: Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67(8), 3560-3564(2007).
49. Gilbertson RJ, Rich JN: Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 7(10), 733-736 (2007).
50. Bao S, Wu Q, Sathornsumetee S et al.: Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66, 7843-7848 (2006).
51. Balic M, Lin H, Young L et al.: Most early disseminated cancer cells detected in bone marrow of brcast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12(19), 5615-56121 (2006).
52. Hermann PC, Huber SL, Herrler T et al.: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007).
53. Jain RK, di Tomaso, E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT: Angiogenesis in brain turnouts. Nat. Rev. Neurosci. 8(8), 610-622 (2007).
54. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25(30), 4722-4729 (2007).
55. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al.: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13(4), 1253-1259 (2007).
56. Bauchelor TT, Sorensen AG, di Tomaso E et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1), 83-95 (2007).
57. Calabrese C, Poppleton H, Kocak M et al.: A perivascular niche for brain tumor stem cells. Cancer Cell 11, 69-82 (2007).
58. Mischel PS, Cloughesy T: Using molecular information to guide brain tumor therapy. Nat. Clin. Pract. Neurol. 2(5), 232-233 (2006).
59. Louis DN: Molecular pathology of malignant gliomas. Annu. Rev. Pathol. 1, 97-117 (2006).
60. Liu R, Wang X, Chen GY et al.: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217-226 (2007).
61. Zeppernick F, Ahmadi R, Campos B et al.: Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14(1), 123-129 (2008).
62. Ho MM, Ng AV, Lam S, Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67, 4827-4833 (2007).
63. Hirschmann-Jax C, Foster AE, Wulf GG et al.: A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 101, 14228-14233 (2004).
64. Zhou S, Schuetz JD, Bunting KD et al.: The ABC transporter Bcrp1/ ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat. Med. 7, 1028-1034 (2001).
65. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66, 85-94 (1991).
66. Ginestier C, Hur MH, Charafe-Jauffret E et al.: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (2007).
67. Pearce DJ, Taussig D, Simpson C et al.: Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 23, 752-760 (2005).
68. Diamandis P, Wildenhain J, Clarke ID et al.: Chemical genetics reveals a complex functional ground state of neural stem cells. Nat. Chem. Biol. 3(5), 268-273 (2007).
69. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167-1174 (2006).
70. Pellegatta S, Poliani PL, Corno D et al.: Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res. 66, 10247-10252 (2006).
71. Jiang H, Gomez-Manzano C, Aoki H et al.: Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J. Natl. Cancer Inst. 99(18), 1410-1414 (2007).
72. Roy NS, Cleren C, Singh SK, Yang L, Beal MF, Goldman SA: Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med. 12(11), 1259-1268 (2006).
73. Wicha MS, Liu S, Dontu G: Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 66, 1883-1890 (2006).